减重代谢手术与胰高血糖素样肽-1受体激动剂及死亡率
该观察性回顾性队列研究基于以色列Clalit健康服务电子病历,纳入6070例年龄≥24岁、合并糖尿病和肥胖且无已知心血管疾病的成员,按年龄、性别和临床特征1:1匹配为3035对,比较减重代谢手术(BMS)与GLP-1受体激动剂(GLP-1RAs)启动后的全因死亡和非致命性主要不良心血管事件(MACEs),中位随访6.8年。糖尿病病程≤10年的2371对中,BMS组死亡率低于GLP-1RAs组(HR 0.38;95%CI 0.25-0.58),但模型中纳入随访期体重下降后该关联变为无统计学意义(HR 0.79;95%CI 0.43-1.48);糖尿病病程>10年的664对中未显示BMS优于GLP-1RAs的生存优势(HR 0.65;95%CI 0.39-1.08)。非致命性MACEs风险在两组间无差异(病程≤10年HR 0.74;95%CI 0.49-1.10;病程>10年HR 1.21;95%CI 0.80-1.85)。作者认为,在糖尿病病程≤10年者中BMS与更大的死亡率降低相关,且该关联由更大的体重下降所介导。
要点
- 糖尿病病程≤10年的肥胖合并糖尿病患者中,BMS组全因死亡风险低于GLP-1RAs组(HR 0.38;95%CI 0.25-0.58)。
- 上述死亡关联在模型中纳入随访期体重下降后不再有统计学意义(HR 0.79;95%CI 0.43-1.48),提示由体重下降介导。
- 糖尿病病程>10年者中,BMS较GLP-1RAs未显示生存优势(HR 0.65;95%CI 0.39-1.08)。
- 非致命性MACEs风险在两组间无差异(病程≤10年HR 0.74;95%CI 0.49-1.10;病程>10年HR 1.21;95%CI 0.80-1.85)。
- 研究为观察性回顾性队列,比较对象为第一代GLP-1RAs,结论不能外推至其他代际药物。
适用人群与场景
- 年龄≥24岁、合并糖尿病和肥胖、且无已知心血管疾病的Clalit健康服务成员。
- 排除既往有缺血性心脏病、缺血性卒中或充血性心力衰竭病史者。
- 纳入2008年1月1日至2021年12月31日期间接受BMS或GLP-1RAs治疗者,随访截至2022年12月31日。
研究设计与关键结果
- 研究类型:观察性回顾性队列研究,基于以色列Clalit健康服务电子病历数据。
- 样本量:6070例,按年龄、性别和临床特征1:1匹配为3035对;平均(SD)年龄51.0(9.5)岁,女性3938例(64.9%);中位随访6.8年(IQR 4.1-9.4年)。
- 糖尿病病程≤10年(2371对):BMS组全因死亡风险低于GLP-1RAs组(HR 0.38;95%CI 0.25-0.58);模型中额外纳入随访期体重下降后,关联无统计学意义(HR 0.79;95%CI 0.43-1.48)。
- 糖尿病病程>10年(664对):BMS较GLP-1RAs未显示生存优势(HR 0.65;95%CI 0.39-1.08)。
- 非致命性MACEs:两组风险无差异(糖尿病病程≤10年HR 0.74;95%CI 0.49-1.10;糖尿病病程>10年HR 1.21;95%CI 0.80-1.85)。
证据类型、等级与局限
- 证据类型:观察性回顾性队列研究,非随机对照试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,在糖尿病病程≤10年的肥胖合并糖尿病患者中,BMS与较第一代GLP-1RAs更大的死亡率降低相关,且该关联由更大的体重下降所介导。
- 研究未显示在糖尿病病程>10年者中BMS较GLP-1RAs有生存优势,也未显示两组非致命性MACEs风险存在差异。
- 本研究比较对象为第一代GLP-1RAs,结论不能外推至其他代际的GLP-1RAs。
- 本研究为观察性回顾性队列,非随机对照试验,不能据此确立因果关系。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Evidence regarding the relative effectiveness of bariatric metabolic surgery (BMS) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) in reducing mortality and major adverse cardiovascular events (MACEs) is limited.
OBJECTIVE: To compare all-cause mortality and nonfatal MACEs associated with BMS vs GLP-1RAs for adults with obesity and diabetes and without known cardiovascular disease.
DESIGN, SETTING, AND PARTICIPANTS: This observational, retrospective cohort study was based on data obtained from the electronic medical records of Clalit Health Services (Clalit), the largest health care organization in Israel. The study included 6070 members aged 24 years or older, who had diabetes and obesity and no prior history of ischemic heart disease, ischemic stroke, or congestive heart failure. Patients who underwent BMS and patients who received GLP-1RAs from January 1, 2008, through December 31, 2021, were matched 1:1 by age, sex, and clinical characteristics. Follow-up ended December 31, 2022.
EXPOSURES: Initiation of BMS or GLP-1RAs.
MAIN OUTCOMES AND MEASURES: The primary outcome was all-cause mortality, assessed by multivariate Cox proportional hazards regression models. The secondary outcome was nonfatal MACEs, assessed by multivariate competing risk models.
RESULTS: The study included 3035 matched pairs of patients (total, 6070; mean [SD] age, 51.0 [9.5] years; 3938 women [64.9%]), who were followed up for a median of 6.8 years (IQR, 4.1-9.4 years). Among those with a diabetes duration of 10 years or less (2371 pairs), mortality was lower for those who underwent BMS than for those treated with GLP-1RAs (hazard ratio [HR], 0.38; 95% CI, 0.25-0.58). This association became nonsignificant when weight loss during the follow-up period was also included in the model (HR, 0.79; 95% CI, 0.43-1.48). Among patients with a duration of diabetes longer than 10 years (664 pairs), no survival advantage was demonstrated for BMS over GLP-1RA (HR, 0.65; 95% CI, 0.39-1.08). The risk for nonfatal MACEs did not differ between the treatment groups (HR, 0.74; 95% CI, 0.49-1.10 among patients with a diabetes duration of ≤10 years; HR, 1.21; 95% CI, 0.80-1.85 among patients with a diabetes duration of >10 years).
CONCLUSIONS AND RELEVANCE: In this cohort study, BMS was associated with greater reduced mortality compared with first-generation GLP-1RAs among individuals with a diabetes duration of 10 years or less, mediated via greater weight loss. No differences in the risk for mortality were observed between the treatment modalities among individuals with a longer duration of diabetes, nor in the occurrence of nonfatal MACEs among all patients.
参考来源
- Dicker D, Sagy YW, Ramot N, et al. Bariatric Metabolic Surgery vs Glucagon-Like Peptide-1 Receptor Agonists and Mortality. JAMA Netw Open. 2024. PMID: 38848064. doi:10.1001/jamanetworkopen.2024.15392
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。